Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8+T Cells as the Principal Effectors and a Novel CD4+T-Cell Reactivity
Open Access
- 1 May 2005
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (9) , 5477-5488
- https://doi.org/10.1128/jvi.79.9.5477-5488.2005
Abstract
T-cell memory to Epstein-Barr virus (EBV) was first demonstrated through regression of EBV-induced B-cell transformation to lymphoblastoid cell lines (LCLs) in virus-infected peripheral blood mononuclear cell (PBMC) cultures. Here, using donors with virus-specific T-cell memory to well-defined CD4 and CD8 epitopes, we reexamine recent reports that the effector cells mediating regression are EBV latent antigen-specific CD4+ and not, as previously assumed, CD8+ T cells. In regressing cultures, we find that the reversal of CD23+ B-cell proliferation was always coincident with an expansion of latent epitope-specific CD8+, but not CD4+, T cells; furthermore CD8+ T-cell clones derived from regressing cultures were epitope specific and reproduced regression when cocultivated with EBV-infected autologous B cells. In cultures of CD4-depleted PBMCs, there was less efficient expansion of these epitope-specific CD8+ T cells and correspondingly weaker regression. The data are consistent with an effector role for epitope-specific CD8+ T cells in regression and an auxiliary role for CD4+ T cells in expanding the CD8 response. However, we also occasionally observed late regression in CD8-depleted PBMC cultures, though again without any detectable expansion of preexisting epitope-specific CD4+ T-cell memory. CD4+ T-cell clones derived from such cultures were LCL specific in gamma interferon release assays but did not recognize any known EBV latent cycle protein or derived peptide. A subset of these clones was also cytolytic and could block LCL outgrowth. These novel effectors, whose antigen specificity remains to be determined, may also play a role in limiting virus-induced B-cell proliferation in vitro and in vivo.This publication has 58 references indexed in Scilit:
- Primary Immune Responses by Cord Blood CD4+T Cells and NK Cells Inhibit Epstein-Barr Virus B-Cell Transformation In VitroJournal of Virology, 2002
- CD4+T-Cell Effectors Inhibit Epstein-Barr Virus-Induced B-Cell ProliferationJournal of Virology, 2001
- Role of Cytotoxic T Lymphocytes in Epstein-Barr Virus-Associated DiseasesAnnual Review of Microbiology, 2000
- HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTIONAnnual Review of Immunology, 1997
- Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.The Journal of Experimental Medicine, 1992
- Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.The Journal of Experimental Medicine, 1992
- Expression of Epstein–Barr Virus Transformation–Associated Genes in Tissues of Patients with EBV Lymphoproliferative DiseaseNew England Journal of Medicine, 1989
- Cytotoxic T cell recognition of Epstein‐Barr virus‐infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinantsEuropean Journal of Immunology, 1981
- Cytotoxic T cell recognition of Epstein‐Barr virus‐infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitroEuropean Journal of Immunology, 1981
- HLA-restricted T-cell recognition of Epstein–Barr virus-infected B cellsNature, 1980